Online citations, reference lists, and bibliographies.
← Back to Search

Radiation Dose-volume Effects In The Lung.

L. Marks, S. Bentzen, J. Deasy, F. Kong, J. Bradley, I. S. Vogelius, I. El Naqa, J. Hubbs, J. Lebesque, R. Timmerman, M. Martel, A. Jackson
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The three-dimensional dose, volume, and outcome data for lung are reviewed in detail. The rate of symptomatic pneumonitis is related to many dosimetric parameters, and there are no evident threshold "tolerance dose-volume" levels. There are strong volume and fractionation effects.
This paper references
10.1016/S1043-321X(08)80050-1
Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models
L. Marks (2008)
10.1016/S0360-3016(02)03986-X
Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability.
Y. Seppenwoolde (2003)
10.1016/J.IJROBP.2006.06.002
Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
S. Tucker (2006)
10.1016/J.IJROBP.2006.07.1337
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
S. Wang (2006)
10.1016/S0167-8140(98)00020-6
Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis.
S. L. Kwa (1998)
10.1097/JTO.0b013e318074e4fa
The North American Experience with Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer
R. Timmerman (2007)
10.1016/J.IJROBP.2004.04.037
Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer.
Y. Seppenwoolde (2004)
10.1016/S1053-4296(03)00034-1
Radiation-induced lung injury.
L. Marks (2003)
10.1378/CHEST.124.5.1946
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.
R. Timmerman (2003)
10.1053/J.SEMINONCOL.2005.03.009
Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis.
F. Kong (2005)
10.1016/J.IJROBP.2004.02.066
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?
K. L. Miller (2005)
10.1002/1097-0142(197608)38:2<939::AID-CNCR2820380243>3.0.CO;2-Y
Elective whole lung irradiation in the treatment of osteogenic sarcoma
G. Rab (1976)
10.1016/J.IJROBP.2005.03.026
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.
E. Yorke (2005)
10.1016/0360-3016(78)90003-2
Systemic (half-body) radiation therapy: response and toxicity.
O. Salazar (1978)
10.1016/0360-3016(81)90131-0
Radiation pneumonitis following large single dose irradiation: a re-evaluation based on absolute dose to lung.
J. Van Dyk (1981)
10.1016/J.IJROBP.2005.11.046
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters.
A. Hope (2006)
10.1016/S0360-3016(03)00590-X
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
D. Antonadou (2003)
10.1016/0360-3016(95)02063-2
Interstitial pneumonitis following autologous bone-marrow transplantation conditioned with cyclophosphamide and total-body irradiation.
M. Ozsahin (1996)
10.1016/J.IJROBP.2004.12.023
Challenges in defining radiation pneumonitis in patients with lung cancer.
Z. Koçak (2005)
10.1016/J.IJROBP.2005.02.032
Dose response and factors related to interstitial pneumonitis after bone marrow transplant.
Sagus Sampath (2005)
10.1016/J.IJROBP.2007.04.077
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data.
J. Bradley (2007)
10.1016/0360-3016(78)90002-0
Radiation pneumonitis: experience following a large single dose of radiation.
C. Fryer (1978)
10.1016/J.IJROBP.2006.09.030
Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates.
J. Schallenkamp (2007)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/0360-3016(95)00009-N
Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis.
D. Oetzel (1995)
10.1002/(SICI)1097-0142(20000501)88:9<2135::AID-CNCR20>3.0.CO;2-H
The role of lung perfusion imaging in predicting the direction of radiation‐induced changes in pulmonary function tests
L. Marks (2000)
10.1016/S0167-8140(03)00119-1
Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study.
T. Rancati (2003)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
Normal Tissue Complication Probability
Ioannis Grout (2011)
10.1007/s00066-003-1078-0
A Little to a Lot or a Lot to a Little?
J. Willner (2003)
10.1016/0014-2964(78)90247-5
Irradiation of the lungs as an adjuvant therapy in the treatment of osteosarcoma of the limbs. An E.O.R.T.C. randomized study.
K. Breur (1978)
10.1080/02841860600902213
Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer
R. Timmerman (2006)
10.1002/1097-0142(19880301)61:5<1024::AID-CNCR2820610528>3.0.CO;2-P
Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation
J. M. V. Burgers (1988)
10.1148/RADIOL.2351040248
Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
T. Kim (2005)
10.1016/S0167-8140(97)00162-X
The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy.
T. Wheldon (1998)
10.1016/S0167-8140(03)00132-4
Loco-regional differences in pulmonary function and density after partial rat lung irradiation.
E. M. Wiegman (2003)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1016/S0169-5002(02)00532-9
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
H. Onishi (2003)
10.1200/JCO.2005.07.167
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
B. Movsas (2005)
10.1016/S0360-3016(01)01713-8
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
D. Antonadou (2001)
10.1053/J.SEMINONCOL.2005.11.005
Pulmonary toxicity of chemotherapy.
M. Meadors (2006)
10.1016/S0360-3016(03)01444-5
Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial.
B. Ozturk (2004)
Radiobiological modeling for treatment planning
V Moiseenko (2005)
10.1016/S0360-3016(00)00648-9
Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer.
T. J. Robnett (2000)
10.1186/1748-717X-2-21
Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors
H. Yamashita (2007)
10.1016/S0360-3016(02)03986-X
Biology contributionComparing different NTCP models that predict the incidence of radiation pneumonitis
Y. Seppenwoolde (2003)
10.1200/JCO.1995.13.10.2606
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors.
M. Roach (1995)
10.1016/0360-3016(94)90181-3
Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis.
M. Martel (1994)
10.1016/J.IJROBP.2006.01.051
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
F. Kong (2006)
10.1093/OXFORDJOURNALS.ANNONC.A059286
Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer.
J. Armstrong (1995)
10.1118/1.598908
The Modern Technology of Radiation Oncology: A Compendium for Medical Physicists and Radiation Oncologists
J. V. Dyk (1999)
10.1158/0008-5472.CAN-05-0786
Radiation damage to the heart enhances early radiation-induced lung function loss.
P. van Luijk (2005)
10.1016/J.IJROBP.2005.09.025
Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
K. Tsujino (2006)
10.1016/0167-8140(91)90068-R
The simultaneous boost technique: the concept of relative normalized total dose.
J. Lebesque (1991)
10.1016/S0360-3016(99)00183-2
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
M. Graham (1999)
10.1016/j.radonc.2008.02.005
Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
Sonal Sura (2008)
10.1016/S0360-3016(02)03807-5
Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer.
K. Tsujino (2003)
10.1378/CHEST.125.1.340
Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors.
R. Hara (2004)
10.1016/S0009-9260(60)80061-X
Total thoracic irradiation combined with intravenous injection of autogenous marrow.
K. Newton (1960)
10.1016/S0360-3016(01)01524-3
Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta.
X. Fu (2001)
10.1302/0301-620X.84B1.12211
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy.
G. Bacci (2002)
10.1016/S0360-3016(02)02929-2
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.
E. Yorke (2002)
10.1016/S0009-9260(69)80048-6
An analysis of 40 cases treated by total thoracic irradiation.
K. Newton (1969)
10.1016/J.IJROBP.2005.03.047
Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention.
V. Mehta (2005)
10.1378/CHEST.111.4.1061
Pulmonary radiation injury.
B. Movsas (1997)
10.1016/J.IJROBP.2003.10.005
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
R. Komaki (2004)
10.1158/0008-5472.CAN-04-3466
Pulmonary radiation injury: identification of risk factors associated with regional hypersensitivity.
Alena Novakova-Jiresova (2005)
10.1016/J.IJROBP.2006.12.031
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
S. Yom (2007)
10.1016/S0360-3016(01)01685-6
Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer.
M. L. Hernando (2001)
10.1016/S0360-3016(98)00196-5
Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients.
S. L. Kwa (1998)
10.1080/095530000138448
Quantitative clinical radiobiology of early and late lung reactions.
S. Bentzen (2000)



This paper is referenced by
Utilizing Computed Tomography Image Features to Advance Prediction of Radiation Pneumonitis
S. Krafft (2016)
10.1007/s00066-018-1303-5
Inclusion of dosimetric data as covariates in toxicity-related radiogenomic studies
N. Yahya (2018)
Accuracy and Uncertainty Considerations in Modern Radiation Oncology
J. V. Dyk (2013)
10.1088/2057-1976/AA5BA9
Validating PET segmentation of thoracic lesions-is 4D PET necessary?
M. S. Nielsen (2017)
10.1088/0031-9155/58/1/159
The dependence of optimal fractionation schemes on the spatial dose distribution.
J. Unkelbach (2013)
10.1016/j.semradonc.2012.11.010
Clinical controversies: proton therapy for thoracic tumors.
D. D. De Ruysscher (2013)
10.1016/j.cllc.2012.10.005
Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation.
J. Kharofa (2013)
10.1016/J.RADPHYSCHEM.2018.12.011
Comparison of biologically effective dose for treatment planning in the fixed-beam intensity-modulated radiotherapy and the volumetric-modulated arc therapy for the typical types of cancer
S. Wang (2019)
10.3892/etm.2018.6936
Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging.
L. Guo (2019)
10.3929/ethz-a-010039192
Towards the treatment of moving targets with scanned proton beams
Andreas Schätti (2013)
10.2217/9781780842165
Personalized Management of Lung Cancer
Ritsuko Komaki (2013)
10.1016/j.apradiso.2020.109138
A portable fast neutron irradiation system for tumor therapy.
Shiwei Jing (2020)
10.1097/MD.0000000000004036
Dosimetric evaluation of incidental irradiation to the axilla during whole breast radiotherapy for patients with left-sided early breast cancer in the IMRT era
Jayoung Lee (2016)
10.1016/j.semradonc.2014.12.003
Nondosimetric risk factors for radiation-induced lung toxicity.
F. Kong (2015)
10.3109/0284186X.2013.831185
Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort
S. Tucker (2014)
10.1016/j.radonc.2014.04.012
A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making.
C. Oberije (2014)
10.1016/j.ijrobp.2018.05.049
Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage.
D. Owen (2018)
10.1016/j.adro.2016.10.007
Priority-driven plan optimization in locally advanced lung patients based on perfusion SPECT imaging
M. Matuszak (2016)
10.1120/jacmp.v14i4.4218
Self‐expanding stent effects on radiation dosimetry in esophageal cancer
Samual R. Francis (2013)
10.1016/j.meddos.2016.12.001
Method of predicting the mean lung dose based on a patient׳s anatomy and dose-volume histograms.
A. Zawadzka (2017)
10.1259/bjr.20180431
Development and validation of a decision support tool to select IMRT as radiotherapy treatment planning modality for patients with locoregionally advanced non-small cell lung cancers (NSCLC).
R. Shrimali (2019)
10.5220/0005693502770281
RadioBio data: A Moddicom Module to Predict Tumor Control Probability and Normal Tissue Complication Probability in Radiotherapy
N. Dinapoli (2016)
10.1016/j.ijrobp.2011.11.013
Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
J. Kharofa (2012)
Aalborg Universitet Validating PET segmentation of thoracic lesions-is 4 D PET necessary ?
Nielsén (2017)
10.3389/fonc.2014.00210
Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective
M. Cremonesi (2014)
10.5603/NJO.2018.0012
Radiobiological rationale for stereotactic hypofractionated radiosurgery Part II. Normal tissue tolerance — dose constraints
B. Maciejewski (2018)
ASSESSMENT OF UNCERTAINTY IN PLANNING AND DOSE DELIVERY OF PROTON THERAPY IN AN IROC- HOUSTON QA PHANTOM DUE TO VARIABLE CT TECHNIQUE AND PROTON ENERGY
Mattie M McInnis (2015)
10.1177/0146645318759622
Radiotherapeutic implications of the updated ICRP thresholds for tissue reactions related to cataracts and circulatory diseases
L. Dauer (2018)
10.3390/md16100392
Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues
H. Yu (2018)
10.3892/MCO.2014.475
Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy.
An-Na Tong (2015)
10.1007/s40944-020-00424-5
Investigation of Association Between Cardiac Dose Distribution and Strain/Tissue Doppler Echocardiographic Indices During 1-Year Post-Mastectomy Radiation Therapy Follow-Up in Breast Cancer Patients
Soodabeh Shahidsales (2020)
10.3109/0284186X.2010.500620
A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer
P. M. Rosenschöld (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar